Impact of integrase inhibitors on the HIV epidemic in Asia. Matthew Law APACC, Hong Kong, 27 June 2018
|
|
- Arthur Norton
- 5 years ago
- Views:
Transcription
1 Impact of integrase inhibitors on the HIV epidemic in Asia Matthew Law APACC, Hong Kong, 27 June 2018
2 What might be the impact of integrase inhibitors on the HIV epidemic in Asia Matthew Law APACC, Hong Kong, 27 June 2018
3 ART coverage end 2016 Lorem ipsum WHO WHO 2017 Source: Global Health Observatory ( 3
4 ART use in Asia TAHOD-LITE 10 sites Cambodia, Hong Kong, India, Indonesia, Singapore, South Korea, Taiwan, Vietnam Generalisability 4
5 IeDEA TREAT Asia network 5
6 Region 1: North America Canada United States Region 2: Caribbean, Central and South America Argentina Brazil Chile Haiti Honduras Mexico Peru Region 5: Asia and Australia Australia / NZ Cambodia China Hong Kong India Indonesia Japan Malaysia Philippines Singapore South Korea Taiwan Thailand Vietnam Region 8: West Africa Benin Burkina Faso Côte d Ivoire Gambia Ghana Guinea-Bissau Mali Nigeria Senegal Togo Region 9: Central Africa Burundi Cameroon Rwanda Region 11: Southern Africa Botswana Lesotho Malawi Mozambique South Africa Zambia Zimbabwe Region 10: East Africa Kenya Tanzania Uganda
7 ART use in TAHOD-LITE 33,233 started ART Median 2010 (IQR 2006 to 2012) 69% male Median age 36 years (IQR 30 to 42) Median CD4 154 cells/µl (IQR 49 to 268) 30%NK Median log viral load 5.0 (IQR 4.4 to 5.5) 80%NK 12% anti-hcv (58% not tested) 8% HBsAg (43% not tested) 7
8 Proportion of patients starting ART in period (%) Impact of INSTIs in Asia ART use in TAHOD-LITE First regimen over time NRTI backbone NNRTI NRTI combination d4t+3tc/ftc AZT+3TC/FTC TDF+3TC/FTC ABC+3TC/FTC Other NNRTI EFV NVP Other NNRTI Non-NNRTI 8
9 Proportion of patients starting second ART in period (%) Impact of INSTIs in Asia ART use in TAHOD-LITE Second regimen NRTI backbone Third drug NRTI combination d4t+3tc/ftc AZT+3TC/FTC TDF+3TC/FTC ABC+3TC/FTC Other PI LPV ATV Other PI Non-PI 9
10 Probability of being on second regimen Impact of INSTIs in Asia ART use in Asia First and second regimen durability First regimen Second regimen Years Years
11 Proportion (%) Impact of INSTIs in Asia ART use in TAHOD-LITE First, second and third ART regimen Calendar Year Calendar Year ART regimen First Second Third ART regimen First Second Third 11
12 Proportion (%) Impact of INSTIs in Asia ART use in TAHOD-LITE Current drug class Calendar Year Calendar Year ART class Insti PI NNRTI NRTI Other ART regimen Insti PI NNRTI NRTI Other 12
13
14 ART use in TAHOD-LITE ART coverage overall 40-60% Growing need for good second and third line options Limited INSTI use to present Limited impact on treatment guidelines 14
15 INSTI effectiveness 15
16 INSTI effectiveness INSTI as first-line ART At least equivalent virological suppression Fewer adverse events Better durability DTG and RAL no CYP3A4-associated drug interactions 16 Walmsley et al. NEJM 2013;369: Stellbrink et al. AIDS 2013;27: Clotet et al. Lancet 2014;383: Lennox et al. Ann Intern Med 2014;161: Molina et al. Lancet HIV 2015:2;e Kanters et al. Lancet HIV 2016:3;e510-20
17 INSTI effectiveness INSTI as first-line ART At least equivalent virological suppression Fewer adverse events Better durability DTG and RAL no CYP3A4-associated drug interactions Switch to INSTI non-inferior to continuing suppressive ART Simplify to 2-drug regimen 17 Trottier et al. Antivir Ther 2017:22;
18 INSTI effectiveness INSTI as first-line ART At least equivalent virological suppression Fewer adverse events Better durability DTG and RAL no CYP3A4-associated drug interactions Switch to INSTI non-inferior to continuing suppressive ART INSTI+PI non-inferior to 2N+PI as second line 18 Boyd et al. Lancet 2013:381; Paton et al. NEJM 2014:371; LaRosa et al. Lancet HIV 2016:3;e247-58
19 INSTI effectiveness INSTI as first-line ART At least equivalent virological suppression Fewer adverse events Better durability DTG and RAL no CYP3A4-associated drug interactions Switch to INSTI non-inferior to continuing suppressive ART INSTI+PI non-inferior to 2N+PI as second line 2N+INSTI superior to 2N+PI as second line 19 Aboud et al. DAWNING study. 9 th IAS Conference on HIV Science; 2017; Paris, France.
20 TLD generic fixed dose combination ~US$75 per patient per year in LMICs Cheaper Could we treat more patients for same money? 20
21 Unitaid modelling Lorem ipsum 21
22 ART coverage by sex among adults, 2016 Source: UNAIDS/WHO estimates.
23 TLD fixed dose combination ~US$75 per patient per year in LMICs Generic, fixed dose combination, one pill/day, first and second line ART TLD 2N+EFV Effective PI based third line ART possible 23
24 DAWNING 2N+DTG vs 2N+LPVr Week 24 virological suppression 257/312 (82%) vs 215/312 (69%) DSMB halted the trial 24
25 DAWNING 2N+DTG vs 2N+LPVr Week 24 virological suppression 257/312 (82%) vs 215/312 (69%) DSMB halted the trial Resistance testing at baseline Had to use at least one fully active NRTI 25
26 TLD FDC as second line Resistance testing not available in most LMICs Raises the question of the effectiveness of TLD FDC as second line in a public health approach 26
27 D 2 EFT Intervention Initial design 1:1 allocation of SOC (DRV/r+2NRTI) versus DRV/r+DTG Resistance testing in ~30% of participants Nucleosides rotated per WHO algorithm if no resistance testing 610 total participants, 12% non-inferiority margin, 90% power Primary endpoint 48w with DSMB review of 24w data at 50% accrual
28 D 2 EFT adaptation Multi-arm multi-stage design MAMS design Variable allocation of SOC (DRV/r+2NRTI) versus DRV/r+DTG versus TLD 1,010 total participants, 12% non-inferiority margin, 90% power for arm 1 vs 2, 88% 1 vs 3, 2 vs 3 88% as secondary comparison (i.e. does allow intervention arms to be compared) Primary endpoint 48w with DSMB review of 12w and 24w data at 100 subjects
29 D 2 EFT adaptation David Cooper Mark Polizzotto, Simone Jacoby Absar Noorul 29
30 D 2 EFT global partnership TAHOD-L 30
31 Funding Partnership
32 D 2 EFT timelines Opening of first sites to third arm July 2018 Final sites (new) to third arm quarter or first quarter 2019 Safety readout by July 2019 Accrual complete December 2019 Primary endpoint December
33 DTG and pregnancy Botswana cohort 4 cases of neural tube defects in 426 women receiving DTG at conception Further work underway If confirmed 30-50% of HIV-positive people in our region are women 33
34 Treatment as prevention Could move to widespread use of INSTIs help reduce HIV transmission? 34
35 UNAIDS/WHO estimates HIV testing and care continuum by WHO region (2016)
36 Treatment as prevention Could move to widespread use of INSTIs help reduce HIV transmission? Potentially a bit Increase treatment uptake and durability Increase proportion <1,000 copies/ml 36
37 Conclusion Growing need for effective, simple, cheap second and third line options INSTIs could help meet that need Questions around safety and efficacy remain Really do need further trial and cohort data 37
38 TAHOD-LITE study members PS Ly and V Khol, National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; MP Lee, PCK Li, W Lam and YT Chan, Queen Elizabeth Hospital, Hong Kong SAR; N Kumarasamy, S Saghayam and C Ezhilarasi, Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), YRGCARE Medical Centre, VHS, Chennai, India; S Pujari, K Joshi, S Gaikwad and A Chitalikar, Institute of Infectious Diseases, Pune, India; TP Merati, DN Wirawan and F Yuliana, Faculty of Medicine Udayana University & Sanglah Hospital, Bali, Indonesia; OT Ng, PL Lim, LS Lee and Z Ferdous, Tan Tock Seng Hospital, Singapore; JY Choi, Na S and JM Kim, Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; WW Wong, WW Ku and PC Wu, Taipei Veterans General Hospital, Taipei, Taiwan; CD Do, AV Ngo and LT Nguyen, Bach Mai Hospital, Hanoi, Vietnam; KV Nguyen, HV Bui, DTH Nguyen and DT Nguyen, National Hospital for Tropical Diseases, Hanoi, Vietnam; AH Sohn, JL Ross and B Petersen, TREAT Asia, amfar - The Foundation for AIDS Research, Bangkok, Thailand; R Bijker, A Jiamsakul, D Rupasinghe and MG Law, Kirby Institute, UNSW Sydney, Australia 38
Lessons learned from the IeDEA West Africa Collaboration
Lessons learned from the IeDEA West Africa Collaboration François DABIS with the contribution of Didier Koumavi EKOUEVI INSERM U-897, Bordeaux, France, Programme PACCI, ANRS site, Abidjan, Côte d Ivoire
More informationEvolving Realities of HIV Treatment in Resource-limited Settings
Evolving Realities of HIV Treatment in Resource-limited Settings Papa Salif Sow MD, MSc Department of Infectious Diseases University of Dakar, Senegal Introduction: ARV access in RLS Scale-up of ART has
More informationState of the Network. TREAT Asia Network Annual Meeting Chiang Mai, Thailand October 2008
State of the Network TREAT Asia Network Annual Meeting Chiang Mai, Thailand October 2008 Research Community Education TAHOD Program Update Current recruitment of ~4,000 patients from 17 sites in 12 countries
More informationCurrent State of Global HIV Care Continua. Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2
Current State of Global HIV Care Continua Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2 1) International Association of Providers of AIDS Care
More informationAnnex 2 A. Regional profile: West Africa
Annex 2 A. Regional profile: West Africa 355 million people at risk for malaria in 215 297 million at high risk A. Parasite prevalence, 215 Funding for malaria increased from US$ 233 million to US$ 262
More informationMary-Ann Davies and Matthias Egger on behalf of the IeDEA-SA Collaboration
Mary-Ann Davies and Matthias Egger on behalf of the IeDEA-SA Collaboration www.iedea-sa.org National Institute of Allergy and Infectious Diseases (NIAID) Eunice Kennedy Shriver National Institute of Child
More informationWhat is Treatment Optimisation (TO)
Outline What is treatmen optimisation Why is treatment optimisation important for the future of HIV treatment and care Drugs optimisation Some strategies for moving the TO agend forward Discussion: Why
More informationGaps between Policy and Practice in Managing HIV disease in Asia Pacific
Gaps between Policy and Practice in Managing HIV disease in Asia Pacific Dr. N. Kumarasamy Chief Medical Officer YRGCARE Medical Centre Voluntary Health Services Chief-Chennai Antiviral Research and Treatment
More informationFunding for AIDS: The World Bank s Role. Yolanda Tayler, WB Bi-regional Workshop for the Procurement of ARVs Phnom Penh, Cambodia
Funding for AIDS: The World Bank s Role Yolanda Tayler, WB Bi-regional Workshop for the Procurement of ARVs Phnom Penh, Cambodia Outline New resources needs estimates Bridging the gap Global overview of
More informationComparative Analyses of Adolescent Nutrition Indicators
Comparative Analyses of Adolescent Nutrition Indicators Rukundo K. Benedict, PhD The DHS Program Stakeholders Consultation on Adolescent Girls Nutrition: Evidence, Guidance, and Gaps October 30 31, 2017
More informationDiagnostic Procurement The Clinton Foundation HIV/AIDS Initiative
Diagnostic Procurement The Clinton Foundation HIV/AIDS Initiative 28 October 2008 Geneva 1 CHAI Work in Diagnostics - Context Diagnostic Test Agreements - In 2002 when CHAI was formed, the price of many
More informationTHE CARE WE PROMISE FACTS AND FIGURES 2017
THE CARE WE PROMISE FACTS AND FIGURES 2017 2 SOS CHILDREN S VILLAGES INTERNATIONAL WHERE WE WORK Facts and Figures 2017 205 58 79 families and transit 31 Foster homes 162 8 3 173 214 2 115 159 136 148
More informationTREAT Asia Education and Training Program
TREAT Asia Education and Training Program TREAT Asia Network Annual Meeting Chiang Mai, Thailand 11 November 2011 Phiangjai Boonsuk Education and Training Project Manager Outline TREAT Asia training calendar
More informationAntiviral Therapy 2016; 21: (doi: /IMP3052)
Antiviral Therapy 2016; 21:725 730 (doi: 10.3851/IMP3052) Short communication HIV viral suppression in TREAT Asia HIV Observational Database enrolled adults on antiretroviral therapy at the Social Health
More informationUNAIDS 2013 AIDS by the numbers
UNAIDS 2013 AIDS by the numbers 33 % decrease in new HIV infections since 2001 29 % decrease in AIDS-related deaths (adults and children) since 2005 52 % decrease in new HIV infections in children since
More informationSGCEP SCIE 1121 Environmental Science Spring 2012 Section Steve Thompson:
SGCEP SCIE 1121 Environmental Science Spring 2012 Section 20531 Steve Thompson: steventhompson@sgc.edu http://www.bioinfo4u.net/ 1 First, a brief diversion... Into... how to do better on the next exam,
More informationAnna Maria Geretti on behalf of co-authors Professor of Virology & Infectious Diseases, University of Liverpool Expert Scientist, Roche Pharma
Anna Maria Geretti on behalf of co-authors Professor of Virology & Infectious Diseases, University of Liverpool Expert Scientist, Roche Pharma Research & Early Discovery Funding: Wellcome Trust, National
More informationAttrition and Treatment Outcomes among Perinatally and Behaviourally HIV-infected Adolescents and Youths in Thai National AIDS program
Attrition and Treatment Outcomes among Perinatally and Behaviourally HIV-infected Adolescents and Youths in Thai National AIDS program Sirinya Teeraananchai 1,2, Thanyawee Puthanakit 1,3,4, Suchada Chaivooth
More informationHIV and Harm Reduction in Prisons
HIV and Harm Reduction in Prisons School of Public Health and Community Medicine Professor Kate Dolan Program of International Research and Training National Drug and Alcohol Research Centre UNSW, Sydney,
More informationDOI: /hiv British HIV Association HIV Medicine (2014), 15, ORIGINAL RESEARCH
DOI: 10.1111/hiv.12073 ORIGINAL RESEARCH Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected
More informationPROGRESS REPORT ON THE ROAD MAP FOR ACCELERATING THE ATTAINMENT OF THE MILLENNIUM DEVELOPMENT GOALS RELATED TO MATERNAL AND NEWBORN HEALTH IN AFRICA
5 July 2011 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Sixty-first session Yamoussoukro, Côte d Ivoire, 29 August 2 September 2011 Provisional agenda item 17.1 PROGRESS REPORT ON THE ROAD MAP FOR
More informationSourcing of ARVs & HIV diagnostics. Procurement for Impact P4i
Sourcing of ARVs & HIV diagnostics Procurement for Impact P4i AMDS ANNUAL STAKEHOLDERS AND PARTNERS MEETING 29 September 2014 Global Fund: Procurement for Impact: P4i Our objective was straightforward:
More informationDr. Natella Rakhmanina Senior Technical Advisor, Elizabeth Glaser Pediatric AIDS Foundation October 2018
Dr. Natella Rakhmanina Senior Technical Advisor, Elizabeth Glaser Pediatric AIDS Foundation October 2018 1 Number of young people living with HIV (aged 15 19 years) by mode of HIV acquisition, 25 countries,*
More informationPresentation by Dr Philippe Douste-Blazy. Chair of UNITAID Special Representative of the UN SG for Innovative Financing for Development
Presentation by Dr Philippe Douste-Blazy Chair of UNITAID Special Representative of the UN SG for Innovative Financing for Development The Millennium Goals : Hope for Humanity 2000 UN Millennium Summit
More informationCopyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved ISBN
UNAIDS DATA TABLES 2011 Copyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved ISBN 978-92-9173-945-5 UNAIDS / JC2225E The designations employed and the presentation of
More informationJOINT TB AND HIV PROGRAMMING
JOINT TB AND HIV PROGRAMMING Haileyesus Getahun, WHO. On behalf of the Global Fund Interagency TB and HIV Working Group (Global Fund, PEPFAR, Stop TB Partnership, UNAIDS, WHO) I was admitted in a hospital
More informationOptimizing Paediatric and Adolescent ART: Challenges and Opportunities
Optimizing Paediatric and Adolescent ART: Challenges and Opportunities Dr Nandita Sugandhi ICAP at Columbia University PATA 2017 Continental Summit 24 October, 2017 Johannesburg South Africa Overview What
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationHIV Viral Load Testing Market Analysis. September 2012 Laboratory Services Team Clinton Health Access Initiative
HIV Viral Load Testing Market Analysis September 2012 Laboratory Services Team Clinton Health Access Initiative Agenda Background on Viral Load Testing Growth of Global Viral Load Market Factors Impacting
More informationMain global and regional trends
I N T R O D U C T I O N Main global and regional trends Promising developments have been seen in recent years in global efforts to address the AS epidemic, including increased access to effective treatment
More informationSeizures of ATS (excluding ecstasy ), 2010
Seizures of ATS (excluding ecstasy ), 2010 (countries and territories reporting seizures* of more than 10 kg) 9 5.1 8.7 12.9 Ghana Armenia 0.7 9.9 1 2.1 Syrian Arab Republic Korea (Republic of) Iraq Islamic
More informationExpert Group Meeting on Strategies for Creating Urban Youth Employment: Solutions for Urban Youth in Africa
Expert Group Meeting on Strategies for Creating Urban Youth Employment: Solutions for Urban Youth in Africa Measurement/indicators of youth employment Gora Mboup Global Urban Observatory (GUO) UN-HABITAT
More informationWhat is this document and who is it for?
Measles and Rubella Initiative s Standard Operating Procedures for Accessing Support for Measles and Rubella Supplementary Immunization Activities During 2016 In the context of measles and rubella elimination
More informationMalaria Funding. Richard W. Steketee MACEPA, PATH. April World Malaria Day 2010, Seattle WA
Malaria Funding Richard W. Steketee MACEPA, PATH April World Malaria Day 2010, Seattle WA Malaria Funding Is there a plan? Is there money? Where does the money come from? Is the money moving efficiently?
More informationGlobal summary of the AIDS epidemic, December 2007
Global summary of the AIDS epidemic, December 27 Number of people living with HIV in 27 Total Adults Women Children under 15 years 33.2 million [3.6 36.1 million] 3.8 million [28.2 33.6 million] 15.4 million
More informationHIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR
HIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR 2015 2020 Presented by Vincent Habiyambere (WHO), Biyi Adesina (Avenir Health) and Meghan Wareham (CHAI) on behalf
More informationChallenges and Opportunities to Optimizing the HIV Care Continuum Can We Test and Treat Enough People to Make a Seismic Difference by 2030?
Challenges and Opportunities to Optimizing the HIV Care Continuum Can We Test and Treat Enough People to Make a Seismic Difference by 2030? Reuben Granich, MD, MPH Strategic and Scientific Advisor International
More informationImpact Dashboard - October 2014
Impact Dashboard - 2014 By 2014, PSI and its network members averted an estimated 44.2 million DALYs globally. PSI has met 60.6% of the strategic plan (SP) target to avert 198.7 million DALYs, and 56.4%
More informationRotavirus vaccines: Issues not fully addressed in efficacy trials
Rotavirus vaccines: Issues not fully addressed in efficacy trials TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines Licensed in 2006
More informationPandemic H1N Dr. Maria Neira Global Influenza Programme WHO, Geneva
Pandemic H1N1 2010 Dr. Maria Neira Global Influenza Programme WHO, Geneva WHO Role during pandemic (H1N1) 2009 Under the International Health Regulations (2005) Detect event (notification by Member States
More informationAcquired HIV Drug Resistance in children in Asia
Acquired HIV Drug Resistance in children in Asia Jintanat Ananworanich, MD, PhD Pediatrician/Immunologist Deputy Director in Scientific Affairs, HIV-NAT Chief, SEARCH The Thai Red Cross AIDS Research Centre
More informationImpact Dashboard - August 2014
Impact Dashboard - By, PSI and its network members averted an estimated 29.7 million DALYs globally. PSI has met 53.3% of the strategic plan (SP) target to avert 198.7 million DALYs, and 53.0% of the SP
More informationDTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone
DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone Aboud M, 1 Brites C, 2 Lu H, 3 Supparatpinyo K, 4 Hercilla L, 5 Sievers J, 1 Nascimento MC, 1 Hopking J, 6 Underwood
More informationUndetectable = Untransmittable. Mariah Wilberg Communications Specialist
Undetectable = Untransmittable Mariah Wilberg Communications Specialist Undetectable=Untransmittable PLWH who get and stay undetectable have effectively no risk of transmitting HIV to their sex partners
More informationEligibility List 2018
The Global Fund s 2017-2022 strategy and allocation-based approach enables strategic investment to accelerate the end of HIV/AIDS, tuberculosis and malaria and build resilient and sustainable systems for
More informationICM: Trade-offs in the fight against HIV/AIDS
ICM: Trade-offs in the fight against HIV/AIDS 1 As the HIV/AIDS pandemic enters its 25 th year, both the number of infections and number of deaths due to the disease continue to rise. Despite an enormous
More informationTHE FUTURE OF ADULT MORTALITY UNDER THE AIDS THREAT: ESTIMATING AND PROJECTING INCIDENCE; PROJECTING MORTALITY WITH HIV/AIDS *
UN/POP/MORT/2003/11 2 September 2003 ENGLISH ONLY WORKSHOP ON HIV/AIDS AND ADULT MORTALITY IN DEVELOPING COUNTRIES Population Division Department of Economic and Social Affairs United Nations Secretariat
More informationFebruary Health Impact Report 2010
February Health Impact Report 1,391,742 Feb'10 DALYs: 7.5% of strategic target goal is 14% 26% decrease from Feb'09 Feb' 10 DALYs include: :: 1,350,675 product s :: 41,067 BCC DALYs todate in 9 countries:
More informationComplementary Interventions (CIV) HIV Reporting FY12 Q2
Complementary Interventions (CIV) HIV Reporting FY Q Fiscal Year 0 quarter was the second quarter that Complementary Interventions tracked HIV Reimbursable Reporting. There were countries that submitted
More informationEXPLANATION OF INDICATORS CHOSEN FOR THE 2017 ANNUAL SUN MOVEMENT PROGRESS REPORT
UNICEF / Zar Mon Annexes EXPLANATION OF INDICATORS CHOSEN FOR THE 2017 ANNUAL SUN MOVEMENT PROGRESS REPORT This report includes nine nutrition statistics, as per the 2017 Global Nutrition Report. These
More informationAIDS in Africa. An Update. Basil Reekie
AIDS in Africa An Update Basil Reekie Contents General Statistics The trend of HIV in Africa Ugandan experience UNAIDS 2006 Latest African Statistics by Country HIV Intervention Light at the end of the
More informationANNEX 3: Country progress indicators
: progress indicators 541 : COUNTRY PROGRESS INDICATORS 2006 REPORT ON THE GLOBAL AIDS EPIDEMIC Annex 3 : COUNTRY PROGRESS INDICATORS As of March 2006, 115 countries had reported indicators on progress
More informationHIV Clinical Management: Antiretroviral Therapy and Drug Resistance
HIV Clinical Management: Antiretroviral Therapy and Drug Resistance Judith S. Currier, MD, MSc Professor of Medicine University of California, Los Angeles Disclosures: Research Grant from Theratechnologies
More informationPRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT
PRIORITIES FOR HIV/AIDS PROCUREMENT AND PRODUCT DEVELOPMENT Dr Chewe Luo MMed (Paeds), Mtrop Paed, PhD Senior Adviser and Team Leader Country Programme Scale up HIV Section Programme Division UNICEF, NY
More informationEnding the AIDS Epidemic in Adolescents
Ending the AIDS Epidemic in Adolescents Eastern and Southern Africa Regional Update on the ALL IN Overview 13 October 2015 AIDS-related deaths has declined for all age groups Except adolescents! Eastern
More informationEpidemiology and economics: modelling the scenarios for the end of AIDS
Epidemiology and economics: modelling the scenarios for the end of AIDS Controlling the HIV Epidemic with Antiretrovirals: from consensus to implementations London, England September 22, 2013 Reuben Granich,
More informationThe Coming Crisis in Antibiotics. Ramanan Laxminarayan European Parliament Conference June 2017
The Coming Crisis in Antibiotics Ramanan Laxminarayan European Parliament Conference June 2017 D Costa, Nature, 2011 Clonal spread of S. pneumoniae 23F Finland Cleveland France BM4200 1978? Spain
More informationReview of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo UNICEF New York City, USA
Review of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo UNICEF New York City, USA Review of recent changes in WHO and national paediatric care guidelines Dr. Chewe Luo MMed
More information511,000 (57% new cases) ~50,000 ~30,000
Latest global TB estimates - 2007 (Updated Mar 2009) All forms of TB Greatest number of cases in Asia; greatest rates per capita in Africa Multidrug-resistant TB (MDR-TB) Estimated number of cases 9.27
More informationUpdate on PMTCT. African Health Profession Regulatory Collaborative for Nurses and Midwives. Johannesburg, Republic of South Africa, June 18-22, 2012
PMTCT Update Update on PMTCT Margarett Davis, MD, MPH Chief, Maternal and Child Health Branch Division of Global HIV/AIDS Centers for Disease Control and Prevention (CDC) African Health Profession Regulatory
More informationValue of post-licensure data to assess public health value Example of rotavirus vaccines
Value of post-licensure data to assess public health value Example of rotavirus vaccines TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationInternational Epidemiology Databases to Evaluate AIDS
International Epidemiology Databases to Evaluate AIDS General overview and cancer projects involving AI FG-AI4H Focus Group AI for Health PD Dr. Julia Bohlius Institute of Social and Preventive Medicine,
More informationProjected Demand for HIV Diagnostic Tests
Projected Demand for HIV Diagnostic Tests John Stover, Yu Teng, Adebiyi Adesina, Eline Korenromp On behalf of the Diagnostics Forecasting Technical Working Group (CDC, CHAI, GFATM, PfSCM, UNAIDS, UNICEF,
More information( A JICA-IRRI-PhilRice Initiative) Presented by Noel Magor, Head Unit Impact Acceleration and Training Center, IRRI
( A JICA-IRRI-PhilRice Initiative) Presented by Noel Magor, Head Unit Impact Acceleration and Training Center, IRRI Long partnership between; IRRI & PhilRice IRRI & JICA PhilRice & JICA The Season Long
More informationProcedure for Expedited Review of imported pre-qualified vaccines for use in national immunization programmes
Procedure for Expedited Review of imported pre-qualified vaccines for use in national immunization programmes Dr Nora Dellepiane/Dr Anil Kumar Chawla WHO/HQ-Geneva, Switzerland 1 Expedited review procedure
More informationElimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014
Elimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014 Outline Background History of prevention of mother to child
More informationGlobal Fund ARV Fact Sheet 1 st June, 2009
Global Fund ARV Fact Sheet 1 st June, 2009 This fact sheet outlines the principles and approach in determining the number of people on antiretroviral drugs (ARVs) for HIV/AIDS treatment, with a breakdown
More information10 Years of Laboratory Capacity Building. September 6-11 th, 2015 Les Pensieres, Veyrier-du-Lac, France
10 Years of Laboratory Capacity Building 6 th Advanced Course on Diagnostics September 6-11 th, 2015 Les Pensieres, Veyrier-du-Lac, France John N. Nkengasong, Ph.D Associate Director for Laboratory & Chief,
More informationGlobal Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive
Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive DR. Nicholas Muraguri OGW, MD,MPH, MBA, PhD (c) Director, Global Plan Secretariat www.zero-hiv.org
More informationTRACKING THE HIV/AIDS EPIDEMIC: ISSUES, CHALLENGES and FUTURE DIRECTIONS. November 2015 CHIPTS
TRACKING THE HIV/AIDS EPIDEMIC: ISSUES, CHALLENGES and FUTURE DIRECTIONS November 2015 CHIPTS CHINA Mortality trends HIV/AIDS mortality increase 1/100,000 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 0-14 15-49
More informationAboubacar Kampo Chief of Health UNICEF Nigeria
Aboubacar Kampo Chief of Health UNICEF Nigeria Many thanks to UNICEF colleagues in Supply Division-Copenhagen and NY for contributing to this presentation Thirty-five countries are responsible for 98%
More informationCopyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved
UNAIDS DATA TABLES 2011 Copyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved UNAIDS / JC2225E The designations employed and the presentation of the material in this publication
More informationWORLD COUNCIL OF CREDIT UNIONS 2017 STATISTICAL REPORT
WORLD COUNCIL OF CREDIT UNIONS 2017 STATISTICAL REPORT THE GLOBAL NET WORK OF CREDIT UNIONS AND FINANCIAL COOPERATIVES MEMBERSHIP AT A GLANCE World Council builds, champions, defends and grows a global
More informationIX. IMPROVING MATERNAL HEALTH: THE NEED TO FOCUS ON REACHING THE POOR. Eduard Bos The World Bank
IX. IMPROVING MATERNAL HEALTH: THE NEED TO FOCUS ON REACHING THE POOR Eduard Bos The World Bank A. INTRODUCTION This paper discusses the relevance of the ICPD Programme of Action for the attainment of
More informationHIV in Women: A Global View of the HIV Epidemic
Training Course in Reproductive Health / Sexual Health Research Geneva 2006 HIV in Women: A Global View of the HIV Epidemic George Schmid, M.D., M.Sc. Department of HIV/AIDS World Health Organization Geneva,
More informationGlobal reductions in measles mortality and the risk of measles resurgence
Global reductions in measles mortality 2000 2008 and the risk of measles resurgence Measles is one of the most contagious human diseases. In 1980 before the use of measles vaccine was widespread, there
More informationPneumococcal Conjugate Vaccine: Current Supply & Demand Outlook. UNICEF Supply Division
Pneumococcal Conjugate Vaccine: Current Supply & Demand Outlook UNICEF Supply Division Update: October 2013 0 Pneumococcal Conjugate Vaccine (PCV) Supply & Demand Outlook October 2013 Update Key updates
More informationTT Procured by UNICEF
TT TT Procured by UNICEF 2001-08 250,000,000 200,000,000 150,000,000 100,000,000 50,000,000 0 2001 2002 2003 2004 2005 2006 2007 2008 Routine SIA TT historical demand and forecast overview Upcoming Tender
More informationClosing the loop: translating evidence into enhanced strategies to reduce maternal mortality
Closing the loop: translating evidence into enhanced strategies to reduce maternal mortality Washington DC March 12th 2008 Professor Wendy J Graham Opinion-based decisionmaking Evidence-based decision-making
More informationSexual and reproductive health care: A comparison of providers and delivery points between the African Region and other regions
Core competencies in primary care: Supplement 2 Sexual and reproductive health care: A comparison of providers and delivery points between the African Region and other regions The Core competencies in
More informationHIV in Women: A Global View of the HIV Epidemic
HIV in Women: A Global View of the HIV Epidemic George Schmid, M.D., M.Sc. Department of HIV/AIDS World Health Organization Geneva, Switzerland Schmidg@who.int Training Course in Sexual and Reproductive
More informationExperiences on Workforce Development in Other Regions
Experiences on Workforce Development in Other Regions The USA Experience John MacArthur, MD, MPH (EIS 98) Director Thailand MOPH US CDC Collaboration CDC/Southeast Asia Regional Office Epidemic Intelligence
More informationAchieving undetectable: what questions remain in scaling-up HIV virologic treatment monitoring?
!! SUPPLEMENTARY MATERIAL FOR ISSUE BRIEF: Achieving undetectable: what questions remain in scaling-up H virologic treatment? Supplementary material includes national recommendations on infant diagnosis,
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationMANAGING HIV IN CHILDREN: BEST PRACTICES
MANAGING HIV IN CHILDREN: BEST PRACTICES Dr. Mo Archary Paediatric Infectious Diseases Specialist University of KwaZulu Natal/ King Edward VIII Hospital Overview Global state of paediatric ART Filling
More informationChallenges in the management of treatment-experienced patients in Sub- Saharan Africa: Clinical Perspective
Challenges in the management of treatment-experienced patients in Sub- Saharan Africa: Clinical Perspective Dr. Patricia Aladi Agaba Senior Lecturer, Department of Family Medicine, University of Jos Honorary
More informationמדינת ישראל. Tourist Visa Table
Updated 23/05/2017 מדינת ישראל Tourist Visa Table Tourist visa exemption is applied to national and official passports only, and not to other travel documents. Exe = exempted Req = required Press the first
More informationPROGRESS REPORT ON CHILD SURVIVAL: A STRATEGY FOR THE AFRICAN REGION. Information Document CONTENTS
29 June 2009 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-ninth session Kigali, Republic of Rwanda, 31 August 4 September 2009 Provisional agenda item 9.2 PROGRESS REPORT ON CHILD SURVIVAL: A
More informationCurrent challenges of paediatric HIV care Experiences in Sub-Saharan Africa. Dr. Elizabeth Obimbo University of Nairobi Nairobi, Kenya
Current challenges of paediatric HIV care Experiences in Sub-Saharan Africa Dr. Elizabeth Obimbo University of Nairobi Nairobi, Kenya Current Challenges of Paediatric HIV Care What is Happening in the
More informationO c t o b e r 1 0,
STUDENT VOICES FROM THE FIELD: WORLD HEALTH ORGANIZATION GENEVA, SWITZERLAND O c t o b e r 1 0, 2 0 1 6 M o l l y P e z z u l o University at Albany School of Public Health MPH Epidemiology Candidate 17
More informationRegulatory Capacity Building and Developing Countries: CBER Perspective
Regulatory Capacity Building and Developing Countries: CBER Perspective Karen Midthun, M.D. Director Center for Biologics Evaluation and Research US Food and Drug Administration IOM Meeting Strengthening
More informationGlobal Fund Results Fact Sheet Mid-2011
Global Fund Results Fact Sheet Mid-2011 This fact sheet outlines some of the common questions and answers regarding results reported by Global Fund-supported programs, including the principles and approach
More informationAccess to reproductive health care global significance and conceptual challenges
08_XXX_MM1 Access to reproductive health care global significance and conceptual challenges Dr Lale Say World Health Organization Department of Reproductive Health and Research From Research to Practice:
More informationVarious interventions for controlling sexually transmitted infections have proven effective, including the syndromic
levels, as understaffing is a chronic issue in all the countries that are scaling up male circumcision. Current achievements notwithstanding, it is necessary to reinforce and strengthen national political
More information2006 CONTRACEPTIVE SOCIAL MARKETING STATISTICS
2006 CONTRACEPTIVE SOCIAL MARKETING STATISTICS August 2007 Courtesy of DKT International 1701 K Street, NW Suite 900 Washington, DC 20006 www.dktinternational.org 1 SOCIAL MARKETING STATISTICS 2006 Highlights
More informationOriginal article Improved survival in HIV treatment programmes in Asia
Antiviral Therapy 216; 21:517 527 (doi: 1.3851/IMP341) Original article Improved survival in HIV treatment programmes in Asia Nicole L De La Mata 1 *, Nagalingeswaran Kumarasamy 2, Vohith Khol 3, Oon Tek
More informationHIV and development challenges for Africa Catherine Hankins, Associate Director & Chief Scientific Adviser to UNAIDS
Catherine, Associate Director & Chief Scientific Adviser to Session: Challenges of globalisation, regional integration and development of Africa 10 th Anniversary of the Centre for the Study of Globalisation
More informationUpdate from GAVI Aurelia Nguyen
Update from GAVI Aurelia Nguyen (Copenhagen, Denmark, 27 June 2012) GAVI vaccine support Currently supported vaccines: pentavalent, pneumococcal, rotavirus, meningitis A, human papillomavirus (HPV), rubella,
More information